Schizophrenia Clinical Trials in New York

Showing 21-40 of 151 trials

D-serine AudRem: R33 Phase

NCT05046353

Schizophrenia is a major public health problem associated with cognitive deficits, such as short and long term memory, executive functioning, attention and speed of processing that are amongst the strongest predictors of impaired functional outcome. In addition, schizophrenia patients show reduced "plasticity", defined as reduced learning. D-serine is a naturally occurring activator of the N-methyl-d-aspartate-type glutamate receptors (NMDAR) in the brain, and this project will assess the D-serine treatment over 16 weeks of a program designed to measure auditory plasticity.

SchizophreniaSchizo Affective Disorder

New York State Psychiatric Institute60 participantsStarted Dec 2022

New York, New York, United States

COMPLETEDPhase 2< 1 mile

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

NCT05443724

The primary purpose of this study is to assess the long-term safety and tolerability of oral emraclidine in adult participants with schizophrenia.

Schizophrenia

AbbVie700 participantsStarted Sep 2022

Phoenix, Arizona, United States • Bryant, Arkansas, United States • Little Rock, Arkansas, United States +82 more locations

D-serine AudRem: R33 Phase

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

Schizophrenia Trials in Other Cities

Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia

7-week Study With CT-155 in People With Schizophrenia

A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia

Motivation Skills Training for Schizophrenia

CVN058 Effect on Mismatch Negativity in Schizophrenics

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

A Study of Paliperidone Palmitate 6-Month Formulation

Adjunctive Vortioxetine in Schizophrenia

ACP-104 in Acutely Psychotic Subjects With Schizophrenia

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

Other Conditions in New York